Single blinded semi-field evaluation of MAÏA® topical repellent ointment compared to unformulated 20% DEET against <em>Anopheles gambiae</em>,... (Publications)
topical repellent ointment containing 15% DEET, MAIA((R)) compared to 20% DEET in ethanol using malaria and dengue mosquito vectors in Bagamoyo Tanzania. METHODS: Fully balanced 3 x 3 Latin square design
The consequences of declining population access to insecticide-treated nets (ITNs) on net use patterns and physical degradation of nets after 22... (Publications)
further reduces ITN lifespan. School-age children that commonly harbour gametocytes that mediate malaria transmission are compelled to sleep under unserviceable nets, crowd under nets or remain uncovered
Our Partners | Swiss TPH (Page)
https://www.swisstph.ch/en/about/our-partners
develop new strategies to strengthen health systems and combat poverty-related diseases such as malaria, tuberculosis and HIV/AIDS. A particular focus is on chronic diseases, such as obesity, cardiovascular [...] PNGIMR and Swiss TPH had a successful collaboration since the 1970s, particularly in the areas of malaria and tuberculosis. Swiss TPH is an institutional member of the Buttressing Coalition, a network of [...] CH German Institute for Medical Mission (DIFAM), DE Global Fund to Fight...
Winter Symposium 2019 (Page)
https://www.swisstph.ch/en/about/events/winter-symposium-2019
Sokhna Thiam, Swiss TPH, Senegal 11:40 Malaria and Climate Change in West Africa, Richard M’bra Kouassi, Swiss TPH, Cote d’Ivoire Short Film “WHO: TDR - Preventing Malaria and Schistosomiasis due to Climate
Expertise in Parasitology (Page)
https://www.swisstph.ch/en/services/diagnostic-centre/expertise-in-parasitology
nachgewiesen werden, weshalb die Serologie zur Diagnose einer akuten Malaria ungeeignet ist. Differenzierung verschiedener Malaria-Arten serologisch nicht möglich. Antikörper können Monate bis Jahre p [...] ) Cryptosporidiosis Cyclosporidiosis Cystoisosporiasis Dientamoebiasis Giardiasis Leishmaniasis Malaria Sleeping Sickness (African Trypanosomes) Helminths Angiostrongyliasis Anisakiasis Cysticercosis [...] : 95% Spezifität : 95%, Kreuzreaktionen möglich mit afrikanischen Trypanosomen,...
Smartphone-Based Tool Improves Care of Children in Tanzania (Page)
https://www.swisstph.ch/en/news/20172710-e-poct
recommends treatment based both on clinical signs as well as point-of-care test results. Apart from the malaria rapid diagnostic test, the e-POCT includes tests for anemia, low oxygen, bacterial infections, and
Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease... (Publications)
jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis
Setting Up an Epidemiological Study in Tanzania (Page)
https://www.swisstph.ch/en/impact-stories/setting-up-an-epidemiological-study-in-tanzania
and middle-income countries. Thanks to the better control of infectious disease such as HIV/Aids, malaria, and tuberculosis, the population grows older. A longer life – combined with lifestyle changes in [...] diabetes and lipid profile are assessed. Besides that, all patients are screened for HIV/AIDS, malaria and schistosomiasis. We run some tests in our own point-of-care laboratory and send the collected
Modelling the Dynamics of SARS-CoV-2 in All of Its Twists and Turns (Page)
https://www.swisstph.ch/en/impact-stories/modelling-the-dynamics-of-sars-cov-2-in-all-of-its-twists-and-turns
she has been focusing on malaria for many years – developing analyses and different mathematical models to support product development and to assess vaccines and drugs for malaria. A pandemic pivot When
Winter Symposium 2020 (Page)
https://www.swisstph.ch/en/about/events/winter-symposium-2020
a Public Private Partnership from Manufacturer to Health Facility, Hans Rietveld, Medicines for Malaria Venture 09:40 Stock-Outs in Switzerland, Enea Martinelli, pharmaSuisse Session 2 | Supply Chains